BioSpace News Archive

Drug Development

BeiGene Initiates Global Phase III Trial of Anti-PD-1 Antibody Tislelizumab in Patients With Hepatocellular Carcinoma

The Phase 3 trial is designed to compare the efficacy and safety of tislelizumab versus sorafenib as a potential first-line treatment in patients with unresectable HCC.

January 2, 2018
·
6 min read
FDA

Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP

The Phendimetrazine Tartrate approval is from an Elite ANDA filed approximately six years ago.

January 2, 2018
·
3 min read
Drug Development

Juniper Pharma Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress

Juniper Pharma today provided financial guidance for 2018, reflecting continued strength in the Company’s core businesses, JPS and CRINONE, and provided an overview of strategic priorities for 2018.

January 2, 2018
·
6 min read
Biotech Bay

Atara Biotherapeutics Announces Proposed Offering of Common Stock - Jan. 2, 2018

The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

January 2, 2018
·
3 min read
Neovasc Inc. Receives NASDAQ Notification Regarding Minimum Bid Requirements

Neovasc announced today that it has received written notification Nasdaq notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.

January 2, 2018
·
7 min read
Deals

Bio-Techne Acquires Atlanta Biologicals

Bio-Techne announced today that it has acquired all of the stock of Atlanta Biologicals and its affiliated company, Scientific Ventures.

January 2, 2018
·
4 min read
LSKB Announces Official Nonproprietary Naming of Apatinib (YN968D1): RIVOCERANIB

LSKB announced that it has adopted the nonproprietary/generic name “rivoceranib” for its small molecule angiogenesis inhibitor commonly known as apatinib and YN968D1.

January 2, 2018
·
3 min read
The Medivir Board is Seeking Issue Authorizations to Increase the Company’s Funding Flexibility and Calls for an Extraordinary General Meeting

Medivir today announces a notice for an Extraordinary General Meeting, to be held on 26 January 2018, with a proposal for the Meeting to authorize the Board of Directors to resolve on a directed share issue of not more than 20 percent of the number of shares of series B.

January 2, 2018
·
3 min read
FDA

Masimo Announces CE Marking and Release of Oxygen Reserve Index rainbow Lite Sensors

ORi is the first noninvasive and continuous parameter to provide insight into a patient’s oxygen reserve in the moderate hyperoxic range.

January 2, 2018
·
8 min read
Medivir’s Series A Shares to be Converted Into Series B Shares

The conversion will be completed as soon as possible following the Extraordinary General Meeting in Medivir to be held on 26 January 2018.

January 2, 2018
·
2 min read